Amgen would not disclose details about which product teams or therapeutic areas are affected by the cuts. SVB Leerink analyst Geoffrey Porges questioned Amgen during its year-end sales call yesterday about rumored commercial field reductions, asking whether the cutbacks stem from a shift to digital-oriented promotions rather than in-person detailing. Murdo Gordon, EVP of global commercial operations, acknowledged the reorganization without giving specifics and said the company looked at its "overall commercial model" with an eye to "making it more productive and making it more efficient." CFO Peter Griffith did note the digital efforts will lead to a decrease in expenses, with SG&A declines "due to changes in our commercial model, including an increased focus on digital efforts." Gordon pointedly said Amgen is not compromising its "ability to have a competitive share of voice in our field facing interactions both in the medical side, both on the commercial side in front of the customer."